Skip to main content

PDS Biotechnology Corporation (PDSB) Stock Forecast

Data as of May 9, 2026

Healthcare · Current price $1.25 (+10.09%)

Consensus Target
$9.00
Upside
+617.1%
Analysts
3
Rating
Buy(2.00)

Price Target Range

Low $9.00High $9.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

PDSB vs Sector & Market

MetricPDSBHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count3819
Target Upside+617.1%+1710.2%+16.4%
P/E Ratio-1.453.3027.60

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$11M$11M$11M1
2027-12-31$23M$23M$23M1
2028-12-31$4M$4M$4M1
2029-12-31$107M$107M$107M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.67$-0.67$-0.672
2027-12-31$-0.69$-0.69$-0.692
2028-12-31$-0.86$-0.67$-0.482
2029-12-31$0.45$0.45$0.451

Frequently Asked Questions

What is the analyst consensus for PDSB?

The consensus among 3 analysts covering PDS Biotechnology Corporation (PDSB) is Buy with an average price target of $9.00.

What is the highest price target for PDSB?

The highest analyst price target for PDSB is $9.00.

What is the lowest price target for PDSB?

The lowest analyst price target for PDSB is $9.00.

How many analysts cover PDSB?

3 analysts have issued ratings for PDS Biotechnology Corporation in the past 12 months.

Is PDSB a buy or sell right now?

Based on 3 analyst ratings, PDSB has a consensus rating of Buy (2.00/5) with a +617.1% upside to the consensus target of $9.00.

What are the earnings estimates for PDSB?

Analysts estimate PDSB will report EPS of $-0.67 for the period ending 2026-12-31, with revenue estimated at $11M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.